Tiotropium bromide is the only long-acting muscarinic antagonist (LAMA) approved for treatment of patients aged ≥6 years old who have symptoms of uncontrolled asthma. Results from several clinical trials have found that once-daily inhaled tiotropium bromide is safe and efficacious in 6- to 17-year-olds with symptomatic asthma despite treatment with inhaled corticosteroids, with or without other medications. There are still few available studies investigating the impact of tiotropium bromide treatment in preschool children with suboptimal control. In this narrative review, we summarize the pharmacological effects of the LAMA tiotropium bromide, provide an overview about current asthma studies at different pediatric ages, and describe future research needs.
Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma / Santamaria, Francesca; Ziello, Carla; Lorello, Paola; Bouchè, Cristina; Borrelli, Melissa. - In: FRONTIERS IN PEDIATRICS. - ISSN 2296-2360. - 10:(2022), p. 896865.
Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma
Francesca Santamaria
Primo
Conceptualization
;Carla ZielloSecondo
Software
;Paola LorelloFormal Analysis
;Melissa BorrelliUltimo
Writing – Original Draft Preparation
2022
Abstract
Tiotropium bromide is the only long-acting muscarinic antagonist (LAMA) approved for treatment of patients aged ≥6 years old who have symptoms of uncontrolled asthma. Results from several clinical trials have found that once-daily inhaled tiotropium bromide is safe and efficacious in 6- to 17-year-olds with symptomatic asthma despite treatment with inhaled corticosteroids, with or without other medications. There are still few available studies investigating the impact of tiotropium bromide treatment in preschool children with suboptimal control. In this narrative review, we summarize the pharmacological effects of the LAMA tiotropium bromide, provide an overview about current asthma studies at different pediatric ages, and describe future research needs.File | Dimensione | Formato | |
---|---|---|---|
Santamaria.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Dominio pubblico
Dimensione
592.11 kB
Formato
Adobe PDF
|
592.11 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.